Caribou Biosciences Halts CAR-T Pipeline and Cuts Staff Amid Funding Freeze
Caribou Biosciences is shutting down its clinical pipeline and laying off staff after failing to secure capital for late-stage trials. The company, which developed off-the-shelf cell therapies, is now seeking strategic alternatives like a merger or asset sale. Its stock plummeted following the announcement.